Flying The Web For News.
  • Happy Holidays
    Happy Holidays
  • Career Exam Study
    Career Exam Study
  • 2024 Presidential Election
    2024 Presidential Election
  • E-commerce Guide
    E-commerce Guide
  • Dropshipping Guide
    Dropshipping Guide
  • Microsoft Exam
    Microsoft Exam
  • IT Career News
    IT Career News
+ Larger Font | - Smaller Font
Share

Globe NewsWire News Distribution Service


This press release was updated to reflect the correct dosing schedule of the NKX019 investigator-sponsored clinical trial. As previously disclosed, patients enrolled in this trial will receive three doses of NKX019 on Days 0, 7, and 14.


Posted: 2024-08-14 01:03:00

Get Full News Story On GlobeNewsWire Press Release Service



Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.



Related News Stories From The Web And More

Related Bing News Search Results

Press Release: Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights - Newscast

Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2

Thu, 05 Dec 2024 03:01:00 GMT Statements contained in this press release ... Nkarta’s filings with the Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of Nkarta’s Quarterly Report ...

Nkarta, Inc. (NKTX)

Fri, 22 Nov 2024 08:00:00 GMT SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced ...

Nkarta to Participate in an Upcoming Investor Conference

Tue, 12 Nov 2024 05:03:00 GMT A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days.





Blow Us A Whistle